Revolutionizing Alzheimer's Disease and Clinical Trials Through Biomarkers

Overview

Journal Alzheimers Dement (Amst)

Date 2016 May 31

PMID 27239522

Citations 53

Authors

Niklas Mattsson

Maria C Carrillo

Robert A Dean

Michael D Devous Sr

Tania Nikolcheva

Pedro Pesini

Hugh Salter

William Z Potter

Reisa S Sperling

Randall J Bateman

Lisa J Bain

Enchi Liu

Affiliations

Soon will be listed here.

Abstract

The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts.

Citing Articles

An experimental framework for conjoint measures of olfaction, navigation, and motion as pre-clinical biomarkers of Alzheimer's disease.

Biljman K, Gozes I, Lam J, Li V J Alzheimers Dis Rep. 2025; 8(1):1722-1744.

PMID: 40034341 PMC: 11863766. DOI: 10.1177/25424823241307617.

Novel Biomarkers for Alzheimer's Disease: Plasma Neurofilament Light and Cerebrospinal Fluid.

Abukuri D Int J Alzheimers Dis. 2024; 2024:6668159.

PMID: 38779175 PMC: 11111307. DOI: 10.1155/2024/6668159.

Which neuroimaging and fluid biomarkers method is better in theranostic of Alzheimer's disease? An umbrella review.

Mohammadi H, Ariaei A, Ghobadi Z, Charkhat Gorgich E, Rustamzadeh A IBRO Neurosci Rep. 2024; 16:403-417.

PMID: 38497046 PMC: 10940808. DOI: 10.1016/j.ibneur.2024.02.007.

Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.

Rodriguez-Vieitez E, Kumar A, Malarte M, Ioannou K, Rocha F, Chiotis K Methods Mol Biol. 2024; 2785:195-218.

PMID: 38427196 DOI: 10.1007/978-1-0716-3774-6_13.

Delayed primacy recall performance predicts Alzheimer's disease pathology from unimpaired cognitive baseline.

Bruno D, Gicas K, Jauregi-Zinkunegi A, Mueller K, Lamar M Alzheimers Dement (Amst). 2024; 16(1):e12524.

PMID: 38239330 PMC: 10795090. DOI: 10.1002/dad2.12524.

References

Price J, Morris J . Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999; 45(3):358-68. DOI: 10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x. View

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

DeMattos R, Bales K, Cummins D, Dodart J, Paul S, Holtzman D . Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001; 98(15):8850-5. PMC: 37524. DOI: 10.1073/pnas.151261398. View

Price J, Ko A, Wade M, Tsou S, McKeel D, Morris J . Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol. 2001; 58(9):1395-402. DOI: 10.1001/archneur.58.9.1395. View

Dodart J, Bales K, Gannon K, Greene S, DeMattos R, Mathis C . Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002; 5(5):452-7. DOI: 10.1038/nn842. View

Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

Dubois B, Feldman H, Jacova C, DeKosky S, Barberger-Gateau P, Cummings J . Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6(8):734-46. DOI: 10.1016/S1474-4422(07)70178-3. View

Hardy J, Allsop D . Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991; 12(10):383-8. DOI: 10.1016/0165-6147(91)90609-v. View

Bateman R, Klunk W . Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics. 2008; 5(3):381-90. PMC: 2588423. DOI: 10.1016/j.nurt.2008.05.009. View

10.

Mosconi L, Pupi A, de Leon M . Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci. 2008; 1147:180-95. PMC: 2661241. DOI: 10.1196/annals.1427.007. View

11.

Shaw L, Vanderstichele H, Knapik-Czajka M, Clark C, Aisen P, Petersen R . Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009; 65(4):403-13. PMC: 2696350. DOI: 10.1002/ana.21610. View

12.

Schneider J, Arvanitakis Z, Leurgans S, Bennett D . The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009; 66(2):200-8. PMC: 2812870. DOI: 10.1002/ana.21706. View

13.

Perrin R, Fagan A, Holtzman D . Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009; 461(7266):916-22. PMC: 2810658. DOI: 10.1038/nature08538. View

14.

Morris J, Roe C, Grant E, Head D, Storandt M, Goate A . Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009; 66(12):1469-75. PMC: 2798814. DOI: 10.1001/archneurol.2009.269. View

15.

Jack Jr C, Knopman D, Jagust W, Shaw L, Aisen P, Weiner M . Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010; 9(1):119-28. PMC: 2819840. DOI: 10.1016/S1474-4422(09)70299-6. View

16.

Blennow K, Hampel H, Weiner M, Zetterberg H . Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010; 6(3):131-44. DOI: 10.1038/nrneurol.2010.4. View

17.

Rinne J, Brooks D, Rossor M, Fox N, Bullock R, Klunk W . 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010; 9(4):363-72. DOI: 10.1016/S1474-4422(10)70043-0. View

18.

Hampel H, Frank R, Broich K, Teipel S, Katz R, Hardy J . Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010; 9(7):560-74. DOI: 10.1038/nrd3115. View

19.

Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P . CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. J Alzheimers Dis. 2010; 22(4):1281-8. DOI: 10.3233/JAD-2010-101293. View

20.

Craig-Schapiro R, Perrin R, Roe C, Xiong C, Carter D, Cairns N . YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry. 2010; 68(10):903-12. PMC: 3011944. DOI: 10.1016/j.biopsych.2010.08.025. View